• Something wrong with this record ?

Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

B. Michelsen, S. Georgiadis, D. Di Giuseppe, AG. Loft, MJ. Nissen, F. Iannone, M. Pombo-Suarez, H. Mann, Z. Rotar, KK. Eklund, TK. Kvien, MJ. Santos, B. Gudbjornsson, C. Codreanu, S. Yilmaz, JK. Wallman, CH. Brahe, B. Möller, EG. Favalli, C....

. 2022 ; 74 (7) : 1205-1218. [pub] 20220429

Language English Country United States

Document type Journal Article, Observational Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22025294

OBJECTIVE: There is a lack of real-life studies on interleukin-17 (IL-17) inhibition in psoriatic arthritis (PsA). We assessed real-life 6- and 12-month effectiveness (i.e., retention, remission, low disease activity [LDA], and response rates) of the IL-17 inhibitor secukinumab in PsA patients overall and across 1) number of prior biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), 2) years since diagnosis, and 3) European registries. METHODS: Thirteen quality registries in rheumatology participating in the European Spondyloarthritis Research Collaboration Network provided longitudinal, observational data collected as part of routine care for secondary use. Data were pooled and analyzed with Kaplan-Meier plots, log rank tests, Cox regression, and multiple linear and logistic regression analyses. RESULTS: A total of 2,017 PsA patients started treatment with secukinumab between 2015 and 2018. Overall secukinumab retention rates were 86% and 76% after 6 and 12 months, respectively. Crude (LUNDEX adjusted) 6-month remission/LDA (LDA including remission) rates for the 28-joint Disease Activity Index for Psoriatic Arthritis, the Disease Activity Score in 28 joints using the C-reactive protein level, and the Simplified Disease Activity Index (SDAI) were 13%/46% (11%/39%), 36%/55% (30%/46%), and 13%/56% (11%/47%), and 12-month rates were 11%/46% (7%/31%), 39%/56% (26%/38%), and 16%/62% (10%/41%), respectively. Clinical Disease Activity Index remission/LDA rates were similar to the SDAI rates. Six-month American College of Rheumatology 20%/50%/70% improvement criteria responses were 34%/19%/11% (29%/16%/9%); 12-month rates were 37%/21%/11% (24%/14%/7%). Secukinumab effectiveness was significantly better for b/tsDMARD-naive patients, similar across time since diagnosis (<2/2-4/>4 years), and varied significantly across the European registries. CONCLUSION: In this large real-world study on secukinumab treatment in PsA, 6- and 12-month effectiveness was comparable to that in previous observational studies of tumor necrosis factor inhibitors. Retention, remission, LDA, and response rates were significantly better for b/tsDMARD-naive patients, were independent of time since diagnosis, and varied significantly across the European countries.

Amsterdam University Medical Centres VU University Medical Centre Amsterdam The Netherlands

ASST Gaetano Pini CTO Institute Milan Italy

Centre for Rheumatology Research University Hospital and University of Iceland Reykjavik Iceland

Charles University Prague Czech Republic

Charles University Prague Czech Republic and Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic

DANBIO Registry and Rigshospitalet Glostrup Denmark and Aarhus University Hospital Aarhus Denmark

Diakonhjemmet Hospital Oslo Norway

Geneva University Hospital Geneva Switzerland

GISEA Registry and University of Bari Bari Italy

Helsinki University Hospital and ORTON Orthopaedic Hospital of the Orton Foundation Helsinki Finland

Hospital Clinico Universitario Santiago de Compostela Spain

Karolinska Institutet Stockholm Sweden

Lund University Skåne University Hospital Lund Sweden

Reuma pt Registry and Portuguese Institute of Rheumatology Lisbon Portugal

Reuma pt Registry and Universidade de Lisboa Lisbon Portugal

Rigshospitalet and DANBIO Registry Glostrup Denmark

Rigshospitalet and DANBIO Registry Glostrup Denmark and University of Copenhagen Copenhagen Denmark

Rigshospitalet Glostrup Denmark

Rigshospitalet Glostrup Denmark and University of Copenhagen Copenhagen Denmark

Rigshospitalet Glostrup Denmark Hospital of Southern Norway Trust Kristiansand Norway and Diakonhjemmet Hospital Oslo Norway

Selcuk University School of Medicine Selcuklu Turkey

Spanish Society of Rheumatology Madrid Spain

Uludağ University Bursa Turkey

Universitätsklinik für Rheumatologie Immunologie und Allergologie Inselspital Bern Switzerland

University Medical Centre Ljubljana Ljubljana Slovenia

University of Aberdeen Aberdeen UK

University of Iceland and Landspitali University Hospital Reykjavik Iceland

University of Medicine and Pharmacy Carol Davila Bucharest Romania

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025294
003      
CZ-PrNML
005      
20221031101326.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/acr.24560 $2 doi
035    __
$a (PubMed)33460531
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Michelsen, Brigitte $u Rigshospitalet, Glostrup, Denmark, Hospital of Southern Norway Trust, Kristiansand, Norway, and Diakonhjemmet Hospital, Oslo, Norway $1 https://orcid.org/0000000301032840
245    10
$a Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries / $c B. Michelsen, S. Georgiadis, D. Di Giuseppe, AG. Loft, MJ. Nissen, F. Iannone, M. Pombo-Suarez, H. Mann, Z. Rotar, KK. Eklund, TK. Kvien, MJ. Santos, B. Gudbjornsson, C. Codreanu, S. Yilmaz, JK. Wallman, CH. Brahe, B. Möller, EG. Favalli, C. Sánchez-Piedra, L. Nekvindova, M. Tomsic, N. Trokovic, EK. Kristianslund, H. Santos, TJ. Löve, R. Ionescu, Y. Pehlivan, GT. Jones, I. van der Horst-Bruinsma, LM. Ørnbjerg, M. Østergaard, ML. Hetland
520    9_
$a OBJECTIVE: There is a lack of real-life studies on interleukin-17 (IL-17) inhibition in psoriatic arthritis (PsA). We assessed real-life 6- and 12-month effectiveness (i.e., retention, remission, low disease activity [LDA], and response rates) of the IL-17 inhibitor secukinumab in PsA patients overall and across 1) number of prior biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), 2) years since diagnosis, and 3) European registries. METHODS: Thirteen quality registries in rheumatology participating in the European Spondyloarthritis Research Collaboration Network provided longitudinal, observational data collected as part of routine care for secondary use. Data were pooled and analyzed with Kaplan-Meier plots, log rank tests, Cox regression, and multiple linear and logistic regression analyses. RESULTS: A total of 2,017 PsA patients started treatment with secukinumab between 2015 and 2018. Overall secukinumab retention rates were 86% and 76% after 6 and 12 months, respectively. Crude (LUNDEX adjusted) 6-month remission/LDA (LDA including remission) rates for the 28-joint Disease Activity Index for Psoriatic Arthritis, the Disease Activity Score in 28 joints using the C-reactive protein level, and the Simplified Disease Activity Index (SDAI) were 13%/46% (11%/39%), 36%/55% (30%/46%), and 13%/56% (11%/47%), and 12-month rates were 11%/46% (7%/31%), 39%/56% (26%/38%), and 16%/62% (10%/41%), respectively. Clinical Disease Activity Index remission/LDA rates were similar to the SDAI rates. Six-month American College of Rheumatology 20%/50%/70% improvement criteria responses were 34%/19%/11% (29%/16%/9%); 12-month rates were 37%/21%/11% (24%/14%/7%). Secukinumab effectiveness was significantly better for b/tsDMARD-naive patients, similar across time since diagnosis (<2/2-4/>4 years), and varied significantly across the European registries. CONCLUSION: In this large real-world study on secukinumab treatment in PsA, 6- and 12-month effectiveness was comparable to that in previous observational studies of tumor necrosis factor inhibitors. Retention, remission, LDA, and response rates were significantly better for b/tsDMARD-naive patients, were independent of time since diagnosis, and varied significantly across the European countries.
650    12
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
650    12
$a antirevmatika $x terapeutické užití $7 D018501
650    12
$a psoriatická artritida $x diagnóza $x farmakoterapie $7 D015535
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-17 $x antagonisté a inhibitory $7 D020381
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Georgiadis, Stylianos $u Rigshospitalet, Glostrup, Denmark
700    1_
$a Di Giuseppe, Daniela $u Karolinska Institutet, Stockholm, Sweden
700    1_
$a Loft, Anne G $u DANBIO Registry and Rigshospitalet, Glostrup, Denmark, and Aarhus University Hospital, Aarhus, Denmark
700    1_
$a Nissen, Michael J $u Geneva University Hospital, Geneva, Switzerland
700    1_
$a Iannone, Florenzo $u GISEA Registry and University of Bari, Bari, Italy $1 https://orcid.org/0000000304745344
700    1_
$a Pombo-Suarez, Manuel $u Hospital Clinico Universitario, Santiago de Compostela, Spain
700    1_
$a Mann, Herman $u Charles University, Prague, Czech Republic
700    1_
$a Rotar, Ziga $u University Medical Centre Ljubljana, Ljubljana, Slovenia
700    1_
$a Eklund, Kari K $u Helsinki University Hospital and ORTON Orthopaedic Hospital of the Orton Foundation, Helsinki, Finland
700    1_
$a Kvien, Tore K $u Diakonhjemmet Hospital, Oslo, Norway $1 https://orcid.org/0000000284413093
700    1_
$a Santos, Maria J $u Reuma.pt Registry and Universidade de Lisboa, Lisbon, Portugal $1 https://orcid.org/0000000279461365
700    1_
$a Gudbjornsson, Bjorn $u Centre for Rheumatology Research (ICEBIO), University Hospital and University of Iceland, Reykjavik, Iceland
700    1_
$a Codreanu, Catalin $u University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
700    1_
$a Yilmaz, Sema $u Selcuk University School of Medicine, Selcuklu, Turkey
700    1_
$a Wallman, Johan K $u Lund University, Skåne University Hospital, Lund, Sweden $1 https://orcid.org/0000000249152924
700    1_
$a Brahe, Cecilie H $u Rigshospitalet and DANBIO Registry, Glostrup, Denmark
700    1_
$a Möller, Burkhard $u Universitätsklinik für Rheumatologie, Immunologie und Allergologie, Inselspital, Bern, Switzerland $1 https://orcid.org/0000000187696167
700    1_
$a Favalli, Ennio G $u ASST Gaetano Pini-CTO Institute, Milan, Italy
700    1_
$a Sánchez-Piedra, Carlos $u Spanish Society of Rheumatology, Madrid, Spain
700    1_
$a Nekvindova, Lucie $u Charles University, Prague, Czech Republic, and Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
700    1_
$a Tomsic, Matija $u University Medical Centre Ljubljana, Ljubljana, Slovenia
700    1_
$a Trokovic, Nina $u Helsinki University Hospital and ORTON Orthopaedic Hospital of the Orton Foundation, Helsinki, Finland
700    1_
$a Kristianslund, Eirik K $u Diakonhjemmet Hospital, Oslo, Norway
700    1_
$a Santos, Helena $u Reuma.pt Registry and Portuguese Institute of Rheumatology, Lisbon, Portugal
700    1_
$a Löve, Thorvardur J $u University of Iceland and Landspitali University Hospital, Reykjavik, Iceland
700    1_
$a Ionescu, Ruxandra $u University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
700    1_
$a Pehlivan, Yavuz $u Uludağ University, Bursa, Turkey
700    1_
$a Jones, Gareth T $u University of Aberdeen, Aberdeen, UK $1 https://orcid.org/0000000300167591
700    1_
$a van der Horst-Bruinsma, Irene $u Amsterdam University Medical Centres, VU University Medical Centre, Amsterdam, The Netherlands
700    1_
$a Ørnbjerg, Lykke M $u Rigshospitalet and DANBIO Registry, Glostrup, Denmark
700    1_
$a Østergaard, Mikkel $u Rigshospitalet, Glostrup, Denmark, and University of Copenhagen, Copenhagen, Denmark
700    1_
$a Hetland, Merete L $u Rigshospitalet and DANBIO Registry, Glostrup, Denmark, and University of Copenhagen, Copenhagen, Denmark
773    0_
$w MED00172712 $t Arthritis care & research $x 2151-4658 $g Roč. 74, č. 7 (2022), s. 1205-1218
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33460531 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031101323 $b ABA008
999    __
$a ok $b bmc $g 1854814 $s 1176584
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 74 $c 7 $d 1205-1218 $e 20220429 $i 2151-4658 $m Arthritis care & research $n Arthritis Care Res $x MED00172712
LZP    __
$a Pubmed-20221017

Find record

Citation metrics

Archiving options